Live prices from 9 UK suppliers, from £35.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Compare 3 prices for PNC-27. Cheapest: £100.00. Average: £153.58.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
| £100.00 | £10.00/mg | In Stock | Free |
Lab Tested
|
— | |||
| £120.00 | £12.00/mg | In Stock | £9.99 |
—
|
— | |||
| £240.75 | £24.08/mg | In Stock | Free |
—
|
— | Unavailable |
More ways to compare PNC-27
Different views of the same live UK pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Anti-Cancer Peptide | p53-HDM-2 Disruptor
PNC-27 is an experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000. It contains an HDM-2 binding domain from p53 (residues 12-26) linked to a cell-penetrating domain. The peptide selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes, forming pores that cause cell necrosis. Critically, PNC-27 has no effect on normal cells because healthy cells don't express HDM-2 on their membranes. Research shows effectiveness against pancreatic cancer, breast cancer, leukemia, and melanoma.
PNC-27 exploits a unique vulnerability of cancer cells: the presence of HDM-2 (human double minute 2, also called MDM2) on their cell surface. The peptide's p53 residues adopt a conformation that binds directly to membrane-bound HDM-2, inducing transmembrane pore formation. This causes rapid tumor cell necrosis (not apoptosis). Additionally, PNC-27 enters cancer cells and disrupts mitochondrial membranes. Normal cells lack surface HDM-2 expression and are completely spared.
PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research.
Demonstrated effectiveness against breast cancer cell lines.
Induces necrosis of K-562 leukemia cells through HDM-2 binding.
Shows selective targeting of melanoma cells.
Most effective against cancers with high membrane HDM-2 expression.
Model compound for studying cancer-selective therapies.
PNC-27 is currently in preclinical research stages. All dosing data comes from in vitro and animal model studies. No human dosing protocols have been approved. The peptide has shown tumor eradication in nude mice xenograft models.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Research protocol | Variable by study | Research protocols | IP or direct tumor injection (research) |
Potential for combination therapy being researched.
Combination studies not yet published.
Binding to membrane HDM-2 begins
Pore formation and cancer cell necrosis
Tumor reduction in animal models
Human clinical trials not yet conducted
PNAS
PNC-27 binds membrane-bound HDM-2, inducing pore formation and cancer cell necrosis while sparing normal cells.
PubMed
PNC-27 also enters cancer cells and disrupts mitochondrial membranes.
Annals of Clinical & Laboratory Science
PNC-27 induces necrosis of K-562 leukemia cells lacking p53 through p53-independent pathway.
PubMed
PNC-27 binds HDM-2 in p53 peptide-like structure, induces selective membrane-pore formation leading to cancer cell lysis.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.